Fundraising Fox
Edwards Lifesciences
NYSE: EWIrvine, US · Delaware corporation · 3 known investors
Find your way into Edwards Lifesciences
Each arrow is one introduction. Sign up to fill in the first one.
Ask Yoshiyuki Sakuraba to introduce you to Huimin Wang
You →Yoshiyuki · together at Varinos, Inc. →Huimin
Ask Jamie Chen to introduce you to Donald E. Bobo, Jr.
You →Jamie · together at Edwards Lifesciences →Donald
Sign up to find every way you can get introduced to Edwards Lifesciences
- Your email: who you already know at Edwards Lifesciences, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Edwards Lifesciences team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Edwards Lifesciences develops innovative medical technologies for treating cardiovascular disease, focusing on structural heart interventions. The company serves patients and healthcare providers globally through partnerships with clinicians and healthcare stakeholders.
Founders & leadership
Board
Investors · 3
Reported raises · per SEC filings
Form D private placements$307.2M disclosed across 2 rounds · 2017–2018
▶$34.9MraisedJun 2018 · 25 investors · BiotechnologyRule 506(b)
- William J. LinkDirector
- Kieran T. GallahueDirector
- Jean-Luc LemercierExecutive Officer
- Leslie S. HeiszDirector
- Donald E. Bobo, Jr.Executive Officer
- Nicholas J. ValerianiDirector
- Steven R. LorangerDirector
- Wesley W. von SchackDirector
- Martha H. MarshDirector
- Catherine M. SzymanExecutive Officer
- Larry L. WoodExecutive Officer
- Michael A. MussallemExecutive Officer, Director
- Huimin WangExecutive Officer
- Scott B. UllemExecutive Officer
- Offering amount
- $34.9M
- Amount sold
- $34.9M
- First sale
- May 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$272.4MraisedFeb 2017 · 25 investors · BiotechnologyRule 506(b)
- Nicholas J. ValerianiDirector
- William J. LinkDirector
- Steven R. LorangerDirector
- Donald E. Bobo, Jr.Executive Officer
- Wesley W. von SchackDirector
- Scott B. UllemExecutive Officer
- Larry L. WoodExecutive Officer
- Leslie S. HeiszDirector
- Huimin WangExecutive Officer
- Catherine M. SzymanExecutive Officer
- John T. CardisDirector
- Bernard J. ZovighianExecutive Officer
- Michael A. MussallemExecutive Officer, Director
- Patrick VerguetExecutive Officer
- Kieran GallahueDirector
- Martha H. MarshDirector
- Offering amount
- $272.4M
- Amount sold
- $272.4M
- First sale
- Jan 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
The Edwards Lifesciences mafia →13 people who came through Edwards Lifesciences went on to found or lead other companies.
Related companies · 2
Companies working in the same space as Edwards Lifesciences.
Acquisitions · 5
Early investors' stakes continue via these dealsCardiAQ Valve Technologies developed a transcatheter mitral valve replacement system enabling minimally invasive treatment of mitral valve disease without open-heart surgery.
CardiAQ Valve Technologies developed a transcatheter mitral valve replacement system that could be implanted in a beating heart without open-heart surgery, using an anchoring mechanism engaging native valve anatomy.
Embrella Cardiovascular developed a cerebral embolic protection device inserted via the brachial or radial artery to deflect embolic debris during transcatheter heart valve procedures, reducing stroke risk. The company was founded in 2007 and based in Wayne/Malvern, PA.
Embrella Cardiovascular was a Pennsylvania-based medical device startup that developed the Embrella Embolic Deflector System, a disposable aortic device to deflect embolic material and reduce stroke risk during transcatheter heart valve replacement procedures.
University of Maryland spin-out commercializing minimally invasive image-guided surgical tool for beating heart mitral valve repair (acquired by Edwards Lifesciences in December 2017).
Frequently asked questions
- What does Edwards Lifesciences do?
- Edwards Lifesciences develops innovative medical technologies for treating cardiovascular disease, focusing on structural heart interventions. The company serves patients and healthcare providers globally through partnerships with clinicians and healthcare stakeholders.
- Who are Edwards Lifesciences's investors?
- Edwards Lifesciences's investors include ALIVE Israel HealthTech Fund, Peregrine Ventures, Versant Venture AIV Holdings.
- How much funding has Edwards Lifesciences raised?
- Edwards Lifesciences has disclosed $307.2M raised across 2 rounds.
- Where is Edwards Lifesciences headquartered?
- Edwards Lifesciences is headquartered in Irvine, US.